Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
Type:
Grant
Filed:
April 10, 2012
Date of Patent:
October 9, 2012
Assignee:
Stemnion, Inc.
Inventors:
Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
Type:
Grant
Filed:
April 10, 2012
Date of Patent:
October 2, 2012
Assignee:
Stemnion, Inc.
Inventors:
Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
October 2, 2012
Assignee:
Stemnion, Inc.
Inventors:
Diana L. Clarke, Charlotte A. Smith, Vivienne S. Marshall
Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.
Type:
Grant
Filed:
May 13, 2008
Date of Patent:
June 12, 2012
Assignee:
Stemnion, Inc.
Inventors:
George L. Sing, Vivienne S. Marshall, Diana L. Clarke
Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
Type:
Grant
Filed:
November 15, 2011
Date of Patent:
June 12, 2012
Assignee:
Stemnion, Inc.
Inventors:
Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.
Type:
Grant
Filed:
December 1, 2009
Date of Patent:
May 29, 2012
Assignee:
Stemnion, Inc.
Inventors:
Charlotte A. Smith, Catherine J. Trumpower, Vivienne S. Marshall
Abstract: The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
Type:
Grant
Filed:
July 2, 2008
Date of Patent:
April 10, 2012
Assignee:
Stemnion, Inc.
Inventors:
Linda O. Palladino, Diana L. Clarke, Vivienne S. Marshall, Charlotte A. Smith, Martin C. Robson
Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
Type:
Grant
Filed:
November 30, 2009
Date of Patent:
November 15, 2011
Assignee:
Stemnion, Inc.
Inventors:
Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.
Type:
Application
Filed:
March 29, 2006
Publication date:
February 4, 2010
Applicant:
STEMNION, INC.
Inventors:
Diana L. Clarke, Charlotte A. Smith, Richard A. Banas, Vivienne S. Marshall